B-Cell Maturation Antigen
"B-Cell Maturation Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A member of the tumor necrosis factor receptor superfamily found on mature B-LYMPHOCYTES. It has specificity for B CELL ACTIVATING FACTOR and TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
| Descriptor ID |
D053301
|
| MeSH Number(s) |
D12.776.543.750.705.852.760.226
|
| Concept/Terms |
B-Cell Maturation Antigen- B-Cell Maturation Antigen
- B Cell Maturation Antigen
- Maturation Antigen, B-Cell
- Receptors, Tumor Necrosis Factor, Member 17
- Tumor Necrosis Factor Receptor Superfamily, Member 17
- B Cell Maturation Protein A
- BCMA Protein
|
Below are MeSH descriptors whose meaning is more general than "B-Cell Maturation Antigen".
Below are MeSH descriptors whose meaning is more specific than "B-Cell Maturation Antigen".
This graph shows the total number of publications written about "B-Cell Maturation Antigen" by people in this website by year, and whether "B-Cell Maturation Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2018 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "B-Cell Maturation Antigen" by people in Profiles.
-
BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement. Blood Adv. 2025 Mar 11; 9(5):1171-1180.
-
Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma. Leuk Lymphoma. 2024 Dec; 65(12):1789-1800.
-
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth. Nat Commun. 2024 Jan 19; 15(1):615.
-
Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma. Hematol Oncol Clin North Am. 2024 04; 38(2):383-406.
-
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J. 2023 08 09; 13(1):117.
-
Ethical Challenges with Multiple Myeloma BCMA Chimeric Antigen Receptor T Cell Slot Allocation: A Multi-Institution Experience. Transplant Cell Ther. 2023 04; 29(4):255-258.
-
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol. 2023 01; 20(1):49-62.
-
Characterization of BCMA Expression in Circulating Rare Single Cells of Patients with Plasma Cell Neoplasms. Int J Mol Sci. 2022 Nov 03; 23(21).
-
Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study. Lancet Haematol. 2022 Dec; 9(12):e897-e905.
-
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol. 2023 02 20; 41(6):1265-1274.